3 Cases of Fenoverine-Induced Rhabdomyolysis.
- Author:
Ki Ryang NA
1
;
Sarah JEONG
;
Dong Seok JANG
;
Soo Youn LEE
;
Han Kyu LEE
;
Young Mo LEE
;
Kang Wook LEE
;
Young Tai SHIN
Author Information
1. Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea. drngr@cnuh.co.kr
- Publication Type:Case Report
- Keywords:
Rhabdomyolysis;
Fenoverine;
Hepatic dysfunction;
Statin
- MeSH:
Aged;
Female;
France;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Korea;
Liver Cirrhosis;
Male;
Malignant Hyperthermia;
Middle Aged;
Mitochondrial Myopathies;
Muscular Diseases;
Myalgia;
Rhabdomyolysis*;
Risk Factors;
Technetium Tc 99m Medronate
- From:Korean Journal of Nephrology
2005;24(4):680-685
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Fenoverine is a spasmolytic drug. It has been reported as a causative drug for rhabdomyolysis in France and also in Korea. Well known risk factors for fenoverine induced rhabdomyolysis are hepatic dysfunction, renal dysfunction, concomitant use of lipid lowering drug, mitochondrial myopathy, lipid storage myopathy or malignant hyperthermia. We describe the clinical findings of 3 cases of fenoverine-induced rhabdomyolysis. (Case 1) A 78 year-old male patient complained of generalized myalgia after 7 days medication of fenoverine 300 mg, daily. (Case 2) A 72 year-old female who had been on statin medication for 4 years, complained of generalized myalgia and weakness after 1 day medication of 300 mg of fenoverine. (Case 3) A 57 year-old female who was diagnosed with liver cirrhosis, complained of generalized myalgia, after 4 days medication of 300mg of fenoverine. Laboratory and Tc-99m MDP bone scan findings were compatible with rhabdomyolysis in all 3 patients: ARF was complicated in case 2 and 3. The renal function improved with supportive care. As far as our knowledge concerned, case 1 is the first report of fenoverine-induced rhabdomyolysis without previously known risk factors. So we suggest when physicians are prescribing fenoverine, careful monitoring of symptoms and signs of rhabdomyolysis should be taken to all patients.
